Abbreviations: AAV: Adeno-associated viruses, AHD2: aldehyde dehydrogenase; FG: Fluorogold; GFAP: glial fibrillary acidic protein; SN: substantia nigra; TH: tyrosine hydroxylase ABSTRACT Adeno-associated viruses (AAVs) have become powerful tools in neuroscience for both basic research and potential therapeutic use. They have become especially important tools for optogenetic experiments based on their ability to achieve transgene expression in postmitotic neurons with regional selectivity. With the use of appropriate promoter elements they can achieve cellular specificity as well. One population of neurons that plays a central role in human neurodegenerative and psychiatric diseases are the dopamine neurons of the midbrain. To study these neurons in vivo with advanced techniques it would be highly advantageous to characterize an appropriate specific promoter. To this end we have characterized a 2.5 kb sequence of the rat tyrosine hydroxylase (TH) promoter. The rTHp(2.5) promoter induced expression of the fluorescent reporter protein mCherry in SN dopamine neurons. Although it showed excellent specificity in cortex and striatum, where no reporter expression was observed, in the SN region many neurons expressed reporter but not TH. We show that some of the TH negativity is due to the suppression of its expression by the transgene. We conclude that rTHp(2.5) does preferentially label dopamine neurons but its specificity is not complete within the substantia nigra and caution must be used.
Keywords: substantia nigra, dopamine, promoter, tyrosine hydroxylase, AAV Adeno-associated viral (AAV) vectors have become valuable tools in neuroscience not only for the investigation of brain function and mechanisms of disease, but also for their potential clinical use in treating neurodegenerative disorders. For the investigation of brain function viral vector delivery of transgenes to postmitotic neurons is one of the essential procedures for the performance of optogenetic technology (Fenno et al., 2011 , Packer et al., 2013 . AAVs have been especially useful for this purpose (Packer et al., 2013) . In optogenetic experiments target selectivity can be achieved at the regional level by controlling the site of injection, and additional selectivity can be obtained at the cellular level by placing the transgene under the control of a cell specific promoter. For this purpose the expression patterns of the promoter must be known in the context in which it will be used.
One particular class of neurons that has been broadly implicated in human neurological and psychiatric disease is the dopamine neuron group of the ventral mesencephalon.
They are known to degenerate in Parkinson's disease and related disorders, and they have been postulated to play a role in the pathogenesis of schizophrenia, addiction, autism and many other psychiatric disorders. In order to investigate this population of neurons with powerful new optogenetic techniques it would be highly advantageous to identify and characterize a promoter that is selective for the dopaminergic phenotype.
There are a number of possible candidates, including Pitx-3, a transcription factor that is essential for dopamine neuron development (Nunes et al., 2003) . The most well characterized promoter for the dopaminergic system is that of tyrosine hydroxylase (TH) the rate limiting enzyme for catecholamine synthesis. A 2.5 kb rat TH promoter sequence has previously been shown to be capable of inducing transgene expression in substantia nigra (SN) dopamine neurons in rats in vivo (Oh et al., 2009 ). For potential use in targeting dopamine neurons in experimental studies we have here quantified in vivo the sensitivity and specificity of this 2.5 kb rat TH promoter for mesencephalic dopamine neurons. In addition we have examined the stability of its expression over time and the nature of it's off target sites.
EXPERIMENTAL PROCEDURES

Production of AAV viral vector
The vector used for this study was an AAV2/1 hybrid serotype. A plasmid encoding the fluorescent protein mCherry was obtained from Addgene Inc. (Cambridge, MA) mCherry DNA was amplified and cloned into an AAV packaging construct that utilizes the chicken β-actin promoter, and contains a 3' WPRE (pBL). A 2.5 kb sequence of rat TH promoter (rTHp) (spanning from -2543 to + 8) was cloned by PCR amplification from a 9 kb rat TH promoter DNA kindly provided by Dr. K.S. Kim (Harvard Medical School, Belmont, MA) . Following appropriate primers pair were used:
The chicken β-actin promoter was then replaced by the rat 2.5 kb TH promoter to generate the rTHp (2.5)-mCherry construct. All nucleotide sequences in the packaging construct were confirmed before AAV production. AAV was produced by the University of North Carolina Viral Vector Core. The genomic titer of AAV rTHp-mCherry was 1 x 10 12 viral genome/ml.
Intracerebral AAV injections
Adult (8 weeks) males C57BL/6 were obtained from Charles River Laboratories (Wilmington, MA). Mice were anesthetized with ketamine/xylazine solution and placed in a stereotaxic frame (Kopf Instruments, CA) with a mouse adapter. The tip of 5.0µl syringe needle (26S) was inserted to stereotaxic coordinates at AP: -0.35cm, ML:
+0.11cm, DV: -0.37cm (relative to bregma) into the SN; or at AP: +0.09cm, ML:
+0.22cm, DV: -0.25cm (relative to bregma) into the striatum; or at AP: +0.09cm; ML:
+0.22cm; DV: -0.125cm (relative to bregma) into the cortex. Viral vector suspension in a volume of 2.0 µl was injected at 0.1 µl/min over 20 minutes. Thus 2.0 x 10 9 viral genomes were injected. Mice were selected for these investigations, rather than rats, because of the wider availability of mouse mutants and their utility for the implementation of optogenetic techniques.
Intrastriatal FG injections
Five weeks after AAV injection, mice were anesthetized with ketamine/xylazine solution and placed in a stereotaxic frame (Kopf Instruments, CA) with a mouse adapter. A solution of FG (0.4 µg/µl in 0.9% NaCl) was injected by microliter syringe at a rate of 0.5µl/minute by pump for a total dose of 12µg in 3 µl. The injection was performed into the striatum at coordinates AP: +0.09cm; ML: +0.22cm; DV: -0.25cm (relative to bregma). After a wait of 2 minutes, the needle was withdrawn slowly.
Institutional review of animal protocols
All injection procedures, as described above, were approved by the Columbia University Animal Care and Use Committee.
Tissue processing
At 6 weeks and 6 months after AAV injections, mice were deeply anaesthetized and perfused intracardially with 0.9% NaCl followed by 4% paraformaldehyde in 0.1mol/l phosphate buffer, pH7.1. The brain was carefully removed and either the whole brain was post-fixed 48h for vibratome sectioning or blocked into midbrain and forebrain regions, post-fixed 48h (forebrain) or a week (midbrain) and cryoprotected overnight (forebrain) for cryostat sectioning. Serial 50µm thick horizontal sections were then cut on a vibratome; or serial 30µm thick coronal sections were cut on a cryostat after rapidly freezing the brain by immersion in isopentane on dry ice. All sections were processed free-floating. 
Immunohistochemical staining procedures
RESULTS
Expression of the reporter mCherry under the rat 2.5 kb TH promoter in SN dopaminergic neurons
In order to evaluate the sensitivity of the rat 2.5 kb TH promoter for transduction of dopaminergic neurons of the SNpc, we performed immunofluorescence staining for TH and visualized co-localization with mCherry ( Fig. 1) . We confirmed the ability of rTHp(2.5) to induce expression in SNpc dopamine neurons. However, not all THpositive neurons expressed mCherry and conversely not all mCherry-positive profiles were TH-positive. Dopaminergic neurons in the SN are classified into two subpopulations, one group expressing calbindin and localized in the dorsal tier, and a second group expressing aldehyde dehydrogenase (AHD2) and localized in the ventral tier (Gerfen et al., 1987a , Gerfen et al., 1987b , McCaffery and Drager, 1994 . To determine whether patterns of rTHp(2.5) expression were modified by subtype localization, we performed immunofluorescence for these two markers and analyzed mCherry expression (Fig. 2) . We found that mCherry was expressed in both subtypes of dopaminergic neurons without any preferential distribution.
Evaluation of the specificity of rTHp(2.5)
In view of the occasional expression of mCherry in non-TH-positive neurons in SN, we sought to determine its pattern of expression in regions that do not normally have substantial dopamine neuron populations. We performed injections in the striatum and cortex, two regions which under normal conditions contain few, if any, dopaminergic neurons. No mCherry-positive profiles were observed in either of these regions (Fig. 3) .
Moreover, because glia are an important site of off-target effects, we examined mCherry expression in glia identified by immunofluorescence for glial fibrillary acidic protein (GFAP) (Fig. 4) . We demonstrated that rTHp(2.5) does not induce expression of the reporter mCherry in GFAP-positive cells.
Quantitative evaluation of sensitivity and specificity of rTHp(2.5) for TH-positive neurons in the SN
In view of the mixed pattern of expression observed in Fig. 1 we undertook a quantitative evaluation of the sensitivity and specificity of rTHp(2.5) for TH-positive neurons in the SN (Fig. 5) . All mCherry/Nissl-positive and TH-positive neurons were counted and instances of double-labeling were determined. Both dorsal and ventral SNpc and the SNpr were analyzed. The analysis was performed at both 6 weeks ( Fig.   5A ) and 6 months ( Fig. 5B) after AAV injection to assess the stability of expression with time. The sensitivity of the promoter, which represents the percent of mCherry transduction of all TH-positive neurons, was 46% for the total SN and stable with time ( Table 1) . The specificity, the percent of all mCherry/Nissl positive neurons that are also TH-positive, at 6 weeks was only 20% for the total SN. This low number was surprising, because it indicates that 80% of mCherry labeling in the vicinity of the SN is falsepositive, and yet very little false-positive staining had been observed with cortical and striatal injections (see Fig. 3 ).
Some apparent false-positive expression is to be expected based on the limitations of TH immunohistochemistry. For a number of reasons, such as fixation and limited penetration of reagents, positive immunostaining may not be achieved for a given cell, leading to the erroneous conclusion that the presence of mCherry is a false positive.
However, such a possibility is unlikely to account for 80% false positives. Another explanation of the apparent low specificity of rTHp(2.5) could be that transgene expression induces a loss of TH phenotype. Such a possibility could be due to the highly expressed transgene having a competitive advantage over the endogenous TH promoter for essential transcriptional factors. Alternatively, the transgene may usurp cellular translational mechanisms. In order to address this possibility, we identified SN dopaminergic neurons in a non-phenotype-dependent manner by use of the fluorescent neuronal retrograde tracer, Fluorogold (FG) (Sauer and Oertel, 1994, Bowenkamp et al., 1996) . weeks after AAV injection (Fig. 6A) since we have shown that mCherry expression was stable with time. We found that that 38% percent of the population of neurons were double labeled mCherry/Nissl/FG-positive, resulting in a sensitivity of 66% for labeling FG-positive neurons (Table 2 ). This is in contrast to only 46% for labeling TH-positive neurons. The specificity in total SN was 48%, over 2-fold higher than that observed when TH immunostaining was used as the marker for dopaminergic neurons. These results suggest that some of the 'false positive' expression of mCherry in THimmunostained populations may be due to suppression of endogenous phenotype.
To further test this possibility, we performed a triple fluorescence analysis by visualizing simultaneously the reporter mCherry, the retrograde tracer FG and TH immunofluorescence staining (Fig. 6B) . We postulated that all FG-positive profiles were equally likely to be dopaminergic. We would then determine the effect of mCherry positivity on TH expression. This analysis was confined to FG-positive profiles that were closely adjacent to TH-positive neurons to insure that the TH phenotype could be demonstrated within the region of interest. It can be seen in Fig. 6B that there is an inverse relationship between mCherry-positivity and TH expression in FG-positive profiles. This observation was confirmed quantitatively in an analysis of N = 14 FGpositive neurons adjacent to TH-positive ones; of those neurons that expressed mCherry (N = 7) only 2 were TH-positive; of those that were negative for mCherry (N =7) all 7 were positive for TH (p =0.02). Thus we conclude that transgene expression is capable of suppressing the production of endogenous proteins and may therefore cause an underestimation of sensitivity.
rTHp(2.5) induces mCherry expression in GABAergic neurons in the SN
Although some expression of mCherry by rTHp(2.5) in non-TH-positive neurons may be due to false negative immunostaining for TH, or to suppression of its expression, nevertheless such possibilities are unlikely to account for mCherry expression in the SNpr where dopaminergic neurons are sparse and GABAergic neurons are plentiful.
We therefore performed immunofluorescence staining for GABA and confirmed that rTHp(2.5) does express mCherry in these neurons (Fig. 7) .
DISCUSSION
Our results show that rTHp(2.5) has the ability to mediate expression in ventral mesencephalic dopamine neurons as previously reported (Oh et al., 2009) . It is equally effective in the dorsal and ventral subtypes of the SNpc. Its expression is stable in these neurons for up to 6 months.
At the regional level rTHp(2.5) showed excellent specificity as it did not induce expression of reporter in any cell type in either striatum or cortex. At the cellular level it was not expressed in glia. This lack of expression in glia may be in part due to the AAV capsid binding properties, as these viruses are neurotropic (Xiao et al., 1997 , Burger et al., 2004 . Nevertheless to confirm the lack of staining of glia by rTHp(2.5) provides additional assurance that off target effects are unlikely to occur.
AAV2/1 rTHp(2.5) achieved transduction of 40% of TH-positive neurons within the SN.
There are multiple possible reasons why this percentage is not higher. It depends on many aspects of delivery including viral titer, injection site and volume, rate and means of administration. In addition it depends on the transduction efficiency of the AAV serotype. And finally it depends on promoter strength. All of these aspects could be further optimized to improve the results that we have obtained.
We did not anticipate that the specificity of rTHp(2.5) in the SN would be so low, at only 20%, especially given that we had seen no expression of mCherry in non-dopaminergic neurons in either striatum or cortex. As previously discussed, some of the lack of expression of TH in mCherry positive neurons may simply be due to a failure of immunofluorescent staining to identify them. Alternatively, as we have shown, the AAV2/1 mCherry vector itself apparently is able to suppress the expression of the endogenous TH. When SN dopamine neurons are retrogradely labeled with FG, a nonphenotype dependent marker, specificity is substantially improved to 48%. Many of these FG/mCherry-positive profiles were negative for TH. Also in keeping with the possibility that the AAV2/1 mCherry vector itself apparently is able to suppress the expression of the endogenous TH, we have demonstrated that there is an inverse relationship between mCherry positivity and TH expression at the single cell level.
While the above considerations may explain instances of mCherry expression in the absence of TH expression in dopaminergic neurons, nevertheless true false positives were identified as double labeling for mCherry and the neurotransmitter GABA in the SNpr. Why GABAergic neurons in the SN are able to 'host' activation of the TH promoter while those in cortex and striatum do not is unknown. While TH is expressed in some GABAergic neurons of the brain, particularly those in the olfactory bulb (Kosaka et al., 1987) , it is not known to be expressed in GABAergic neurons of the SNpr. It is possible that the 2.5 kb promoter fragment lacks normal repressor elements such that ectopic reporter expression occurs within the SNpr (Kessler et al., 2003) . Ectopic reporter expression in GABAergic neurons of the mesencephalon has also been reported for the 9.0 kb rat TH promoter from which the 2.5 kb fragment is derived (Kim et al., 1993) and for the 9. Although other catecholamine or dopaminergic promoters have been successfully used to mediate expression within dopamine neurons in transgenic mice, including the 9.0 kb sequence developed by Kim and colleagues (Kim et al., 1993 , Oh et al., 2009 ), a 7.8 kb dopamine transporter sequence (Zhuang et al., 2001 , Zhuang et al., 2005 , and a 7.2 kb Pitx-3 sequence (Lin et al., 2012) , these sequences exceed the maximal capacity for AAV constructs of about 4.7 kb (Grieger et al., 2006) . In the context of AAV-based approaches, only the 2.5 kb TH promoter sequence has been used (Oh et al., 2009 , Gompf et al., 2015 . Both Oh and coworkers and Gompf and colleagues found that reporter expression mediated by the 2.5 kb rat TH promoter sequence was observed in non-dopaminergic neurons in the SN. Thus our findings are concordant with these earlier observations, and they provide some insight as to the reasons for this ectopic expression.
CONCLUSIONS
In conclusion we have shown that rTHp(2.5) has the ability to drive expression in ventral mesencephalic dopamine neurons in both the dorsal and ventral tier subtypes with stability over time. However there are some caveats to its use. We find low sensitivity for dopamine neurons, but recognize that this aspect could be improved by optimizing delivery techniques, serotypes and promoter elements. The principal caveat to the use of rTHp(2.5) is that in the vicinity of the mesencephalon off target effects may occur due to expression within GABAergic neurons. Sensitivity, the percent of total TH-positive neurons in which mCherry is expressed, was stable from 6 weeks to 6 months at 46% and 48% respectively. Specificity, the percent of mCherry-positive neurons that also express TH, was surprisingly low at 20% in SN at 6 weeks, and it remained low at 6 months at 15%. Sensitivity for labeling FG-positive neurons in the total SN at 6 weeks was 66%.
Specificity was 48%in SN at 6 weeks, considerably higher than that observed in TH immunostained tissue. 
HIGHLIGHTS
• AAV vectors with specific promoters for neuron phenotypes are powerful tools in neuroscience, particularly in optogenetics
• Midbrain dopamine neurons have great interest because they play a central role in neurodegenerative and psychiatric disease
• To facilitate their study we analyzed specificity and efficiency of a 2.5 kb sequence of rat tyrosine hydroxylase promoter
• Regional specificity was good, as no expression was seen in striatum or cortex, but cellular specificity in SN was only 50%
• This promoter has utility in the study of dopaminergic neurons, but incomplete specificity necessitates caution in its use
